Vandetanib
VEGFRK inhibitor / A potent and selective inhibitor of VEGFR2, (KDR IC50 = 40 nM). Also inhibits fms-like tyrosine kinase 4 (VEGFR3, IC50 = 110 nM) and epidermal growth factor receptor (EGFR/HER1, IC50 = 500 nM) but shows selectivity against a panel of other tyrosine and serine-threonine kinases. Inhibits colony formation in seven cancer cell lines2. Displays anti-angiogenesis activity3.
Biochemicals & reagents
443913-73-3
ZD6474
1) Wedge et al. (2002), ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration; Cancer Res., 62 4645 2) Ciardiello et al. (2003), Antitunmor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase; Clin. Cancer Res., 9 1546 3) Herbst et al. (2007), Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis; Expert Opin. Investig. Drugs, 16 239
-20°C
TARGET: Kinase -- PATHWAY: VEGF -- RESEARCH AREA: Angiogenesis -- DISEASE AREA: Cancer